1052 Cost-effectiveness of epoetin alfa (EPO) and darbepoetin alfa (DARB) based on hematopoietic response rates and cost of therapy

Hout, BA Van; Gagnon, DD; Guastalla, Jean Paul

doi:10.1016/s1359-6349(03)91078-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been several pharmacoeconomic comparisons of epoetin alfa and darbepoetin alfa [23,60,[63][64][65], few studies have compared the cost-effectiveness of all three commercially available erythropoietic proteins in the oncology setting. Two retrospective studies of prescription data both reported greater overall treatment costs with darbepoetin alfa compared with epoetin alfa and beta [66,67].…”

Section: Pharmacoeconomic Comparisonsmentioning

confidence: 99%

Epoetin Beta In Oncology: Examining the Current Evidence

Ludwig

2006

Future Oncol.

View full text Add to dashboard Cite

Anemia is highly prevalent in patients with cancer and its impact on quality of life and long-term outcome in these patients is well documented. Recombinant human erythropoietins, or epoetins, have been used to treat cancer-related or antitumor therapy-induced anemia for many years. Through a combination of clinical studies and extensive experience in the real-life clinical setting, epoetin beta has been shown to be efficacious and well tolerated, increasing hemoglobin levels, reducing the need for transfusion and improving quality of life. This favorable efficacy and safety profile has been demonstrated across a broad range of malignancy types, irrespective of the treatment used (platinum or non-platinum based). The effect of treatment with epoetin beta is rapid, with mean hemoglobin increases of 1 g/dl seen as early as 4 weeks following the start of therapy. Furthermore, there is no evidence that epoetin beta negatively affects overall survival or tumor progression in anemic patients with cancer. The approved 30,000 IU once-weekly dosing regimen (as opposed to the 10,000 IU three-times weekly regimen) provides greater convenience and may result in improved treatment compliance.

show abstract

Section: Pharmacoeconomic Comparisonsmentioning

confidence: 99%

Epoetin Beta In Oncology: Examining the Current Evidence

Ludwig

2006

Future Oncol.

View full text Add to dashboard Cite

show abstract

1052 Cost-effectiveness of epoetin alfa (EPO) and darbepoetin alfa (DARB) based on hematopoietic response rates and cost of therapy

Cited by 1 publication

References 0 publications

Epoetin Beta In Oncology: Examining the Current Evidence

Epoetin Beta In Oncology: Examining the Current Evidence

Contact Info

Product

Resources

About